Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.

Ellen BurgessStefan D AnkerGerasimos FilippatosBertram PittLuis M RuilopeAndreas L BirkenfeldJanet B McGillSylvia E RosasAmer JosephMartin GebelLuke RobertsMarkus F ScheererGeorge L BakrisRajiv Agarwal

Published in: Diabetes care (2022)

Benefits of finerenone compared with placebo on cardiorenal outcomes in patients with CKD and type 2 diabetes were observed irrespective of SGLT2i use.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
chronic kidney disease
insulin resistance
randomized controlled trial
clinical trial
double blind
adipose tissue
metabolic syndrome
phase iii
skeletal muscle
open label
study protocol
placebo controlled